Exelixis (NASDAQ:EXEL – Get Rating) had its target price trimmed by Morgan Stanley from $22.00 to $21.00 in a research report released on Wednesday morning, The Fly reports. The brokerage currently has an equal weight rating on the biotechnology company’s stock. EXEL has been the topic of a number of other reports. Wells Fargo & […]
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders (the “Annual.
State of Michigan Retirement System grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 1.2% in the fourth quarter, HoldingsChannel reports. The fund owned 82,116 shares of the biotechnology company’s stock after buying an additional 1,000 shares during the period. State of Michigan Retirement System’s holdings in Exelixis were worth $1,317,000 […]
Exelixis (EXEL) Advances Board Refreshment Plan streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
StockNews.com downgraded shares of Exelixis (NASDAQ:EXEL – Get Rating) from a buy rating to a hold rating in a research report report published on Thursday morning. Other equities analysts have also recently issued reports about the company. Truist Financial reduced their target price on Exelixis from $35.00 to $32.00 in a research note on Friday, […]